Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,528 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer.
Nishimura M, Toyoda M, Takenaka K, Imamura Y, Chayahara N, Kiyota N, Mukohara T, Kotake T, Tsuji A, Saito K, Saito Y, Minami H. Nishimura M, et al. Cancer Chemother Pharmacol. 2016 Jun;77(6):1165-70. doi: 10.1007/s00280-016-3026-6. Epub 2016 Apr 21. Cancer Chemother Pharmacol. 2016. PMID: 27100735 Free PMC article.
Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging.
Nishimura M, Hayashi M, Mizutani Y, Takenaka K, Imamura Y, Chayahara N, Toyoda M, Kiyota N, Mukohara T, Aikawa H, Fujiwara Y, Hamada A, Minami H. Nishimura M, et al. Oncotarget. 2018 Apr 6;9(26):18540-18547. doi: 10.18632/oncotarget.24928. eCollection 2018 Apr 6. Oncotarget. 2018. PMID: 29719624 Free PMC article.
Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Yokoe T, Kurozumi S, Nozawa K, Ozaki Y, Maeda T, Yazaki S, Onishi M, Fujimoto A, Nakayama S, Tsuboguchi Y, Iwasa T, Sakai H, Ogata M, Terada M, Nishimura M, Onoe T, Masuda J, Kurikawa M, Isaka H, Hagio K, Shimomura A, Okumura Y, Futamura M, Shimokawa M, Takano T. Yokoe T, et al. Among authors: nishimura m. Breast Cancer. 2021 May;28(3):581-591. doi: 10.1007/s12282-020-01192-y. Epub 2021 Jan 2. Breast Cancer. 2021. PMID: 33389616 Free PMC article.
Mitigation of paclitaxel-induced peripheral neuropathy in breast cancer patients using limb-cooling apparatus: a study protocol for a randomized controlled trial.
Funasaka C, Hanai A, Zenda S, Mori K, Fukui M, Hirano N, Shinohara R, Fuse N, Wakabayashi M, Itagaki M, Tomioka Y, Nishina M, Arai Y, Kogawa T, Ozaki Y, Nishimura M, Kobayashi T, Hara F, Takano T, Mukohara T. Funasaka C, et al. Among authors: nishimura m. Front Oncol. 2023 Jul 7;13:1216813. doi: 10.3389/fonc.2023.1216813. eCollection 2023. Front Oncol. 2023. PMID: 37483483 Free PMC article.
Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study.
Aoyama Y, Ozaki Y, Kizawa R, Masuda J, Kawai S, Kurata M, Maeda T, Yoshida K, Yamashita N, Nishimura M, Hosonaga M, Fukada I, Hara F, Kobayashi T, Takano T, Ueno T. Aoyama Y, et al. Among authors: nishimura m. Breast Cancer. 2024 Dec 7. doi: 10.1007/s12282-024-01657-4. Online ahead of print. Breast Cancer. 2024. PMID: 39644440
4,528 results